NDA Filed for Idelalisib for Treating Non-Hodgkin Lymphoma

Gilead Sciences has submitted an NDA to the FDA for its new drug idelalisib, for the use in patients with indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news